Galapagos Shares Soar 3.61% on Revenue Growth, Clinical Trial Data

Galapagos (GLPG) shares surged 3.61% today, marking the second consecutive day of gains, with a total increase of 4.77% over the past two days. The stock price reached its highest level since October 2024, with an intraday gain of 4.03%.

Galapagos reported a significant 20.10% revenue growth, reflecting strong top-line performance. This financial achievement can positively influence investor sentiment and drive the stock price higher.

The company presented new data from Cohort 3 of the ATALANTA-1 clinical trial at ICML 2025, focusing on relapsed/refractory indolent NHL patients. The data showed a high complete response rate, which can boost investor confidence and have a favorable impact on the stock price.

Galapagos announced the appointment of Aaron Cox as the new Chief Financial Officer, effective July 7, 2025. This management change could influence investor sentiment and the company's strategic direction, potentially affecting the stock price.

As of December 31, 2024, Galapagos had reduced its workforce by 37.31% compared to the previous year. This significant reduction in employees could have implications for operational efficiency and cost management, which might impact the company's financial performance and, consequently, its stock price.